Vineet Laboratories Ltd
Incorporated in 2003, Vineet Laboratories Ltd is in designing, developing, manufacturing of API Intermediates and Bulk Drugs
- Market Cap ₹ 49.9 Cr.
- Current Price ₹ 54.1
- High / Low ₹ 89.0 / 46.6
- Stock P/E
- Book Value ₹ 33.4
- Dividend Yield 0.00 %
- ROCE 6.65 %
- ROE 2.31 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Promoter holding has decreased over last quarter: -1.43%
- Promoter holding is low: 36.1%
- Company has a low return on equity of 8.90% over last 3 years.
- Earnings include an other income of Rs.0.99 Cr.
- Working capital days have increased from 73.4 days to 126 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|
0 | 243 | 191 | 212 | 151 | 113 | |
0 | 235 | 178 | 205 | 143 | 111 | |
Operating Profit | -0 | 8 | 13 | 8 | 7 | 2 |
OPM % | 3% | 7% | 4% | 5% | 1% | |
0 | 0 | 0 | 0 | 0 | 1 | |
Interest | 0 | 3 | 2 | 3 | 5 | 5 |
Depreciation | 0 | 2 | 2 | 2 | 3 | 3 |
Profit before tax | -0 | 4 | 9 | 2 | 0 | -5 |
Tax % | 0% | 56% | 29% | 38% | -183% | |
-0 | 2 | 7 | 1 | 1 | -4 | |
EPS in Rs | -0.24 | 1.93 | 7.20 | 1.36 | 1.12 | -4.47 |
Dividend Payout % | 0% | 0% | 14% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -15% |
TTM: | -45% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -24% |
TTM: | -167% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -8% |
1 Year: | -16% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 9% |
Last Year: | 2% |
Balance Sheet
Figures in Rs. Crores
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|
Equity Capital | 0.41 | 9 | 9 | 9 | 9 | 9 |
Reserves | -0 | 17 | 24 | 24 | 26 | 22 |
0 | 12 | 27 | 31 | 44 | 41 | |
0 | 70 | 74 | 51 | 38 | 35 | |
Total Liabilities | 0 | 109 | 133 | 116 | 117 | 107 |
0 | 20 | 21 | 27 | 27 | 26 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 |
0 | 89 | 112 | 89 | 90 | 80 | |
Total Assets | 0 | 109 | 133 | 116 | 117 | 107 |
Cash Flows
Figures in Rs. Crores
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
0 | 27 | 8 | -10 | -11 | |
0 | -8 | -4 | -7 | 0 | |
0 | 19 | 12 | 0 | 11 | |
Net Cash Flow | 0 | 38 | 16 | -16 | -0 |
Ratios
Figures in Rs. Crores
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
Debtor Days | 64 | 69 | 60 | 77 | |
Inventory Days | 73 | 109 | 98 | 158 | |
Days Payable | 114 | 161 | 74 | 103 | |
Cash Conversion Cycle | 23 | 17 | 84 | 131 | |
Working Capital Days | 28 | 28 | 66 | 126 | |
ROCE % | 34% | 23% | 9% | 7% |
Documents
Announcements
-
Disclosure Under Reg 7(2) Of SEBI( Prohibition Of Insider Trading) Regulation, 2015.
22 Nov - Disclosure of share sale by company promoters.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
15 Nov - Newspaper Advertisement in Financial Express ( English Language) and Nava Telangana ( Telugu Language) regarding the Unaudited Standalone Financial Statement for the Second quarter and …
- Outcome Of Board Meeting Held On Wednesday, November 13, 2024 As Required Under Regulation 30 Of SEBI (LODR) Regulations, 2015 13 Nov
-
Board Meeting Outcome for Outcome Of Board Meeting Held On Wednesday, November 13, 2024 As Required Under Regulation 30 Of SEBI (LODR) Regulations, 2015
13 Nov - Resignation of Bhaskara Reddy Karna as Independent Director.
-
Announcement under Regulation 30 (LODR)-Change in Management
13 Nov - Resignation of Bhaskara Reddy Karna as Independent Director.
Product Profile:
a) API Intermediates:[1] Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, Piroctone Olanine
b) Fine Chemicals and Reagents:[2] IPTG, PNPP, X-Gal, ATCA, Butyl Lithium, Furaldehyde, Butylnitrite, Aminouracil, etc.